PMID- 20844469
OWN - NLM
STAT- MEDLINE
DCOM- 20101124
LR  - 20101101
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 90
IP  - 9
DP  - 2010 Nov 15
TI  - Distinct immunohistochemical phenotype of nonmelanoma skin cancers between renal 
      transplant and immunocompetent populations.
PG  - 986-92
LID - 10.1097/TP.0b013e3181f6a0a1 [doi]
AB  - BACKGROUND: Nonmelanoma skin cancers (NMSCs), the most common malignancy in 
      kidney transplant recipients (KTRs), are more frequent and aggressive in KTR than 
      in the general population. These phenomena could be caused by immunosuppressive 
      treatments, both by decreasing immunosurveillance and by a direct oncogenic 
      potential. METHODS: To assess the possible mechanisms involved in the clinical 
      behavior of NMSC in KTR, we compared the tumoral expression of several molecule 
      markers between 106 NMSC (basal cell carcinoma [BCC]; n=55, squamous cell 
      carcinoma [SCC]; n=51) collected from 37 KTR and 51 control patients (CPs) from 
      the general population. Immunohistochemical expression of transforming growth 
      factor beta 1, epidermal growth factor receptor, protein 53 (p53), 
      phospho-p70-S6-kinase, mammalian target of rapamycin (mTOR), and phospho-mTOR 
      (Ser2448) were compared between KTR and CP and were also correlated with 
      immunosuppressive therapy. RESULTS: p53 expression and transforming growth factor 
      beta intensity were greater in SCC from KTR than from CP. In contrast, 
      phospho-mTOR and phospho-p70S6K (Thr421Ser424) expressions were higher in SCC 
      from CP. p53 and phospho-p70S6K (Thr389) expression were higher in BCC from KTR 
      than from CP. Expression of the other biological markers showed no statistically 
      significant differences between SCC and BCC from KTR treated with or without 
      calcineurin inhibitors. CONCLUSIONS: Several prooncogenic markers showed distinct 
      patterns of expression in NMSC from KTR. These differential characteristics could 
      be responsible for the clinical behavior of posttransplantation NMSC. 
      Furthermore, these markers may constitute possible targets for future therapeutic 
      approaches to NMSC in KTR and could help to guide immunosuppressive therapy.
FAU - Gutierrez-Dalmau, Alex
AU  - Gutierrez-Dalmau A
AD  - Department of Nephrology and Renal Transplantation, Hospital Clinic, Institut 
      d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, 
      Barcelona, Spain. agutierrezd@salud.aragon.es
FAU - Revuelta, Ignacio
AU  - Revuelta I
FAU - Ferrer, Berta
AU  - Ferrer B
FAU - Mascaro, Jose M Jr
AU  - Mascaro JM Jr
FAU - Oppenheimer, Federico
AU  - Oppenheimer F
FAU - Albanell, Joan
AU  - Albanell J
FAU - Campistol, Josep M
AU  - Campistol JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Aged
MH  - Carcinoma, Basal Cell/epidemiology/immunology/pathology/surgery
MH  - Carcinoma, Squamous Cell/epidemiology/immunology/pathology/surgery
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunocompetence
MH  - Immunocompromised Host
MH  - Immunosuppressive Agents/therapeutic use
MH  - Kidney Transplantation/*adverse effects/immunology
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Skin Neoplasms/*epidemiology/immunology/parasitology/surgery
EDAT- 2010/09/17 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/09/17 06:00
PHST- 2010/09/17 06:00 [entrez]
PHST- 2010/09/17 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1097/TP.0b013e3181f6a0a1 [doi]
PST - ppublish
SO  - Transplantation. 2010 Nov 15;90(9):986-92. doi: 10.1097/TP.0b013e3181f6a0a1.